UCB and Stanford Medicine are joining forces for a multi-year collaboration to develop unique solutions that combine clinical, real-world, omics, and other data sets — along with the required expertise — to identify which patients will respond best and ultimately, deliver better patient outcomes.
UCB and Stanford Medicine plan to explore digital phenotyping, computational discovery of pathogenic mechanisms, and the disease burden and societal experience for people living with severe diseases like Hidradenitis Suppurativa (HS). Projects will begin in early 2021 with future projects focusing on immunology, neurology, and other emerging areas of interest.
In addition to joint research projects, the collaboration includes workshops and the potential for exchange programs to bring the capabilities, skills, and talent of UCB and Stanford together.
"Through this collaboration with Stanford Medicine, we hope to enable new solutions for people living with severe diseases by solving problems that wouldn't be possible on our own," says Emmanuel Caeymaex, Executive Vice President, Immunology Solutions & Head of U.S. UCB, in a news release. "UCB is committed to creating sustainable value for patients by unleashing the full power of our combined clinical and real-world data and scientific innovation."
"The strategic application of AI and data science presents an opportunity to improve drug development and timely dosing, and uncover new applications for existing therapeutics," says Lloyd Minor, MD, Dean of the Stanford School of Medicine. "In this way, our collaboration with UCB advances Stanford Medicine's vision of Precision Health—a future where we will not only treat disease, but use new technologies to predict, prevent, and cure it precisely."